A nanobowl-supported drug-loaded liposome, a preparation method therefor, and an application thereof. The preparation method for the nanobowl-supported drug-loaded liposome comprises: incubating and ultrasonically treating a nanobowl and a liposome and then successfully encapsulating a drug by utilizing an ammonium sulfate active drug loading method to obtain the nanobowl-supported drug-loaded liposome. The nanobowl-supported drug-loaded liposome can resist the influence of plasma proteins and blood flow shearing forces on drug leakage, enhance the delivery of the drug at a tumor site, improve carrier stability, and improve an anti-tumor curative effect.

A nanobowl-supported drug-loaded liposome, a preparation method therefor, and an application thereof. The preparation method for the nanobowl-supported drug-loaded liposome comprises: incubating and ultrasonically treating a nanobowl and a liposome and then successfully encapsulating a drug by utilizing an ammonium sulfate active drug loading method to obtain the nanobowl-supported drug-loaded liposome. The nanobowl-supported drug-loaded liposome can resist the influence of plasma proteins and blood flow shearing forces on drug leakage, enhance the delivery of the drug at a tumor site, improve carrier stability, and improve an anti-tumor curative effect.

Disclosed is the use of a checkpoint kinase (CHK) inhibitor in combination with i) a poly(ADP)-ribose polymerase inhibitor, and optionally ii) a chemotherapeutic agent such as gemcitabine, in cancer treatment.

Disclosed is the use of a checkpoint kinase (CHK) inhibitor in combination with i) a poly(ADP)-ribose polymerase inhibitor, and optionally ii) a chemotherapeutic agent such as gemcitabine, in cancer treatment.

This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R.sup.1, R.sup.2, and R.sup.3 substituents are reported herein.

This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R.sup.1, R.sup.2, and R.sup.3 substituents are reported herein.

Provided herein are methods and compositions for treating solid tumor cancers.

Provided herein are methods and compositions for treating solid tumor cancers.

Provided herein are methods and compositions for treating solid tumor cancers.

The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.